(EMAILWIRE.COM, August 07, 2018 ) “The genetic disorders segment is expected to grow at the highest rate during the forecast period”

By disease, the viral vector manufacturing market is segmented into cancer, genetic disorders, infectious diseases, and other diseases. During the forecast period, the genetic disorders segment is expected to grow at the highest CAGR owing to the accelerated research activities on various genetic disorders such as hemophilia A and B, sickle cell anemia, and Huntington’s disease.

Browse 50 market data Tables and 22 Figures spread through 107 Pages and in-depth TOC on "Viral Vector Manufacturing Market"
https://www.marketsandmarkets.com/Market-Reports/viral-vector-manufacturing-market-89341986.html

“The pharmaceutical and biopharmaceutical companies to hold the largest share of the market”

Based on end user, the global viral vector manufacturing market is segmented into pharmaceutical and biopharmaceutical companies and research institutes. The pharmaceutical and biopharmaceutical companies segment is expected to hold the largest share of the market in 2018. The successful launch of viral vector gene therapies and a robust pipeline of such therapies are the key factors contributing to the growth of the pharmaceutical and biopharmaceutical companies segment during the forecast period.

“North America is expected to dominate the viral vector manufacturing market in 2018”

In 2018, North America is expected to account for the largest share of 64.8% of the global viral vector manufacturing market. Factors such as a large number of regenerative medicine companies (including gene and cell therapy companies), increasing research activities, rising prevalence of target diseases, and availability of funding are supporting the growth of the viral vector manufacturing market in North America.

Request Sample Pages: https://www.marketsandmarkets.com/requestsample.asp?id=89341986

Break of primary participants was as mentioned below:

By Company Type – Tier 1–40%, Tier 2–30% and Tier 3–30%
By Designation – C-level–20%, Director Level–40%, Others–40%
By Region – North America–50%, Europe–20%, Asia Pacific–20%, RoW–10%
The major players in the global viral vector manufacturing market are Lonza (Switzerland), Merck (Germany), Oxford BioMedica (UK), CGT Catapult (UK), Cobra Biologics (UK), uniQure (Netherlands), FUJIFILM Diosynth Biotechnologies (US), and Spark Therapeutics (US).

Research Coverage:

The report analyzes the viral vector manufacturing market and aims at estimating the market size and future growth potential of this market based on various aspects such as type, disease, application, end user, and region. The report also includes the competitive analysis of the key players in this market along with their company profiles, product offerings, recent developments, and key market strategies.

This report provides insights on the following pointers:

Market Penetration: Comprehensive information on product portfolios offered by key players in the global viral vector manufacturing market. The report analyzes the global viral vector manufacturing market by type, disease, application, end user, and region

Product Innovation: Detailed insights on upcoming trends and product launches in the global viral vector manufacturing market

Market Development: Comprehensive information about the lucrative emerging markets by type, disease, application, and end user

Market Diversification: Exhaustive information about new products, growing geographies, recent developments, and investments in the market

Competitive Assessment: In-depth assessment of market shares and growth strategies of leading players in the global market

Press Release: https://www.marketsandmarkets.com/PressReleases/viral-vector-manufacturing.asp
About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.